Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 3Lung Neoplasms 3Esophageal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solid Tumor, Adult 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Breast Cancer Metastatic 1

Interventions

Oxaliplatin 6Fluorouracil 6Leucovorin 4Capecitabine 4Blood Specimen Collection 4Pafolacianine 3Cisplatin 3Cetuximab 3Bevacizumab 3pembrolizumab 2atezolizumab 2XELOX 2Surveys and Questionnaires 2Standard of Care 2Specimen Handling 2Paclitaxel 2Irinotecan 2IDRX-42 2Gemcitabine 2Folfox protocol 2Endoscopic Mucosal Resection 2Drug Therapy 2Docetaxel 2Carboplatin 2130-nm albumin-bound paclitaxel 2trastuzumab deruxtecan 1sodium thiosulfate 1sodium propionate 1sacituzumab govitecan 1s-formylglutathione hydrolase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Gastrointestinal Neoplasms × patritumab deruxtecan × Clear all
NCT06596694 2026-06-01

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
180 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡